Sonidegib

Identification

Name
Sonidegib
Accession Number
DB09143
Type
Small Molecule
Groups
Approved, Investigational
Description

Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was approved by the FDA for treating basal cell carcinoma in July 2015 and is awaiting approval in the EU.

Structure
Thumb
Synonyms
  • Erismodegib
  • N-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridin-3-yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide
External IDs
LDE 225 / LDE-225 / LDE225 / NVP-LDE 225 / NVP-LDE-225 / NVP-LDE225
Product Ingredients
IngredientUNIICASInChI Key
Sonidegib phosphateW421AI34UW 1218778-77-8RWIVSVMMGFFZIJ-VWDRLOGHSA-N
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
OdomzoCapsule200 mgOralNovartis Europharm Limited2015-08-14Not applicableEu
OdomzoCapsule200 mgOralNovartis Europharm Limited2015-08-14Not applicableEu
OdomzoCapsule200 mg/1OralNovartis2015-07-242017-12-31Us
Approved Generic Prescription Products
Not Available
Approved Over the Counter Products
Not Available
Unapproved/Other Products
Not Available
International/Other Brands
Not Available
Brand mixtures
Not Available
Categories
UNII
0RLU3VTK5M
CAS number
956697-53-3
Weight
Average: 485.507
Monoisotopic: 485.192626198
Chemical Formula
C26H26F3N3O3
InChI Key
VZZJRYRQSPEMTK-CALCHBBNSA-N
InChI
InChI=1S/C26H26F3N3O3/c1-16-14-32(15-17(2)34-16)24-12-9-20(13-30-24)31-25(33)23-6-4-5-22(18(23)3)19-7-10-21(11-8-19)35-26(27,28)29/h4-13,16-17H,14-15H2,1-3H3,(H,31,33)/t16-,17+
IUPAC Name
N-{6-[(2R,6S)-2,6-dimethylmorpholin-4-yl]pyridin-3-yl}-2-methyl-4'-(trifluoromethoxy)-[1,1'-biphenyl]-3-carboxamide
SMILES
[H][[email protected]]1(C)CN(C[[email protected]@]([H])(C)O1)C1=CC=C(NC(=O)C2=CC=CC(=C2C)C2=CC=C(OC(F)(F)F)C=C2)C=N1

Pharmacology

Indication

Sonidegib is approved for use in the US and EU for treatment of adults with locally advanced basal cell carcinoma (BCC) that has recurred post surgery or radiation therapy. It is also approved for adult patients with BCC who are not eligible for surgery or radiation therapy. (2)

Structured Indications
Pharmacodynamics

Sonidegib has been shown to inhibit a transmembrane protein called SMO which plays a role in Hh signal transduction. This has resulted in inhibition of Hh signaling as well as antitumour activity in various animal models. In a transgenic mouse model of islet cell neoplasms, tumour volume was reduce by 95% in mice treated with sonidegib when compared with untreated mice. (2)

Mechanism of action

The hedgehog pathway is involved in many human cancers. Sonidegib effectively inhibits the regulator called smoothened (Smo), preventing the hedgehog pathway from functioning. As a result, tumours that depend on the hedgehog pathway are unable to grow. (1)

TargetActionsOrganism
USmoothened homolog
antagonist
Human
Absorption

Sonidegib is rapidly absorbed in the fasted state with peak concentrations occurring 2-4 hours after administration. (2) However, the total absorption of Sonidegib is low (roughly 6-7%). (1)

Volume of distribution

Estimated volume of distribution = 9166 L (2)

Protein binding

Sonidegib is over 97% bound to plasma proteins, and binding is independent of concentration. (2)

Metabolism

Sonidegib is primarily metabolized via oxidation and amide hydrolysis. (1) The enzyme responsible for the majority of metabolism is the cytochrome P450 (CYP) 3A4 enzyme. (2)

Route of elimination

Around 70% of Sonidegib is eliminated in the feces, while 30% is eliminated in the urine. (2)

Half life

Half-life ~ 28 days (2)

Clearance
Not Available
Toxicity

Adverse events occurred more frequently with higher doses, 800 mg once daily when compared to a lower dose of 200 mg once daily. In the 200 mg group, frequent adverse events (occurring in ≥2% of patients) included: elevated creatine phosphokinase (6%), increased lipase (5%), muscle spasms (3%), asthenia (3%), and hypertension (3%). In the 800 mg group, frequent adverse events included: elevated creatine phosphokinase (13%), increased lipase (5%), weight loss (5%), muscle spasms (5%), decreased appetite (4%), rhabdomyolysis (3%), nausea (3%), hypertension (3%), increased alanine aminotransferase (3%), increased aspartate aminotransferase (3%), fatigue (2%), syncope (2%), anaemia (2%), dehydration (2%), hyperkalaemia (2%) and myalgia (2%). Rhabdomyolysis cases reported by investigators were not confirmed by the adjudication committee on muscle toxicity or the independent safety review. (2)

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Sonidegib.Approved
AmiodaroneThe serum concentration of Sonidegib can be increased when it is combined with Amiodarone.Approved, Investigational
AprepitantThe serum concentration of Sonidegib can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe serum concentration of Sonidegib can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe serum concentration of Sonidegib can be increased when it is combined with Atomoxetine.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Sonidegib.Approved, Investigational
BexaroteneThe serum concentration of Sonidegib can be decreased when it is combined with Bexarotene.Approved, Investigational
BoceprevirThe serum concentration of Sonidegib can be increased when it is combined with Boceprevir.Withdrawn
BortezomibThe serum concentration of Sonidegib can be increased when it is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Sonidegib can be decreased when it is combined with Bosentan.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Sonidegib.Approved
CarbamazepineThe serum concentration of Sonidegib can be decreased when it is combined with Carbamazepine.Approved, Investigational
CeritinibThe serum concentration of Sonidegib can be increased when it is combined with Ceritinib.Approved
ClarithromycinThe serum concentration of Sonidegib can be increased when it is combined with Clarithromycin.Approved
ClemastineThe serum concentration of Sonidegib can be increased when it is combined with Clemastine.Approved
ClotrimazoleThe serum concentration of Sonidegib can be increased when it is combined with Clotrimazole.Approved, Vet Approved
CobicistatThe serum concentration of Sonidegib can be increased when it is combined with Cobicistat.Approved
ConivaptanThe serum concentration of Sonidegib can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe serum concentration of Sonidegib can be increased when it is combined with Crizotinib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Sonidegib.Approved, Investigational
CyclosporineThe serum concentration of Sonidegib can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Sonidegib can be decreased when it is combined with Dabrafenib.Approved
DarunavirThe serum concentration of Sonidegib can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Sonidegib can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Sonidegib can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe serum concentration of Sonidegib can be increased when it is combined with Delavirdine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Sonidegib.Approved
DexamethasoneThe serum concentration of Sonidegib can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Sonidegib.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Sonidegib.Approved
DihydroergotamineThe serum concentration of Sonidegib can be increased when it is combined with Dihydroergotamine.Approved
DiltiazemThe serum concentration of Sonidegib can be increased when it is combined with Diltiazem.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Sonidegib.Approved, Investigational
DoxycyclineThe serum concentration of Sonidegib can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe serum concentration of Sonidegib can be increased when it is combined with Dronedarone.Approved
EfavirenzThe serum concentration of Sonidegib can be decreased when it is combined with Efavirenz.Approved, Investigational
EnzalutamideThe serum concentration of Sonidegib can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe serum concentration of Sonidegib can be increased when it is combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Sonidegib can be decreased when it is combined with Eslicarbazepine acetate.Approved
EtravirineThe serum concentration of Sonidegib can be decreased when it is combined with Etravirine.Approved
FluconazoleThe serum concentration of Sonidegib can be increased when it is combined with Fluconazole.Approved
FluvoxamineThe serum concentration of Sonidegib can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Sonidegib can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Sonidegib can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Sonidegib can be decreased when it is combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Sonidegib can be increased when it is combined with Fusidic Acid.Approved
IdelalisibThe serum concentration of Sonidegib can be increased when it is combined with Idelalisib.Approved
ImatinibThe serum concentration of Sonidegib can be increased when it is combined with Imatinib.Approved
IndinavirThe serum concentration of Sonidegib can be increased when it is combined with Indinavir.Approved
IsavuconazoniumThe serum concentration of Sonidegib can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsradipineThe serum concentration of Sonidegib can be increased when it is combined with Isradipine.Approved
ItraconazoleThe serum concentration of Sonidegib can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Sonidegib can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe serum concentration of Sonidegib can be increased when it is combined with Ketoconazole.Approved, Investigational
LopinavirThe serum concentration of Sonidegib can be increased when it is combined with Lopinavir.Approved
LovastatinThe serum concentration of Sonidegib can be increased when it is combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Sonidegib can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Sonidegib can be decreased when it is combined with Lumacaftor.Approved
MifepristoneThe serum concentration of Sonidegib can be increased when it is combined with Mifepristone.Approved, Investigational
MitotaneThe serum concentration of Sonidegib can be decreased when it is combined with Mitotane.Approved
ModafinilThe serum concentration of Sonidegib can be decreased when it is combined with Modafinil.Approved, Investigational
NafcillinThe serum concentration of Sonidegib can be decreased when it is combined with Nafcillin.Approved
NefazodoneThe serum concentration of Sonidegib can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Sonidegib can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Sonidegib can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Sonidegib can be decreased when it is combined with Nevirapine.Approved
NilotinibThe serum concentration of Sonidegib can be increased when it is combined with Nilotinib.Approved, Investigational
OlaparibThe serum concentration of Sonidegib can be increased when it is combined with Olaparib.Approved
OleandrinAnvirzel may decrease the cardiotoxic activities of Sonidegib.Experimental
OsimertinibThe serum concentration of Sonidegib can be increased when it is combined with Osimertinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Sonidegib.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sonidegib.Approved, Vet Approved
PalbociclibThe serum concentration of Sonidegib can be increased when it is combined with Palbociclib.Approved
PentobarbitalThe serum concentration of Sonidegib can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe serum concentration of Sonidegib can be decreased when it is combined with Phenobarbital.Approved
PhenytoinThe serum concentration of Sonidegib can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PosaconazoleThe serum concentration of Sonidegib can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PrimidoneThe serum concentration of Sonidegib can be decreased when it is combined with Primidone.Approved, Vet Approved
RanolazineThe serum concentration of Sonidegib can be increased when it is combined with Ranolazine.Approved, Investigational
RifabutinThe serum concentration of Sonidegib can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Sonidegib can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Sonidegib can be decreased when it is combined with Rifapentine.Approved
RitonavirThe serum concentration of Sonidegib can be increased when it is combined with Ritonavir.Approved, Investigational
SaquinavirThe serum concentration of Sonidegib can be increased when it is combined with Saquinavir.Approved, Investigational
SildenafilThe serum concentration of Sonidegib can be increased when it is combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Sonidegib can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Sonidegib can be increased when it is combined with Simeprevir.Approved
St. John's WortThe serum concentration of Sonidegib can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Sonidegib can be increased when it is combined with Stiripentol.Approved
SulfisoxazoleThe serum concentration of Sonidegib can be increased when it is combined with Sulfisoxazole.Approved, Vet Approved
TelaprevirThe serum concentration of Sonidegib can be increased when it is combined with Telaprevir.Withdrawn
TelithromycinThe serum concentration of Sonidegib can be increased when it is combined with Telithromycin.Approved
TiclopidineThe serum concentration of Sonidegib can be increased when it is combined with Ticlopidine.Approved
TocilizumabThe serum concentration of Sonidegib can be decreased when it is combined with Tocilizumab.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Sonidegib.Approved, Investigational
VenlafaxineThe serum concentration of Sonidegib can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Sonidegib can be increased when it is combined with Verapamil.Approved
VoriconazoleThe serum concentration of Sonidegib can be increased when it is combined with Voriconazole.Approved, Investigational
ZiprasidoneThe serum concentration of Sonidegib can be increased when it is combined with Ziprasidone.Approved
Food Interactions
Not Available

References

Synthesis Reference
Not Available
General References
  1. Zollinger M, Lozac'h F, Hurh E, Emotte C, Bauly H, Swart P: Absorption, distribution, metabolism, and excretion (ADME) of (1)(4)C-sonidegib (LDE225) in healthy volunteers. Cancer Chemother Pharmacol. 2014 Jul;74(1):63-75. doi: 10.1007/s00280-014-2468-y. Epub 2014 May 10. [PubMed:24817600 ]
  2. Burness CB: Sonidegib: First Global Approval. Drugs. 2015 Sep;75(13):1559-66. doi: 10.1007/s40265-015-0458-y. [PubMed:26323341 ]
External Links
KEGG Drug
D10119
ChemSpider
25027390
BindingDB
50394562
ChEBI
90863
ChEMBL
CHEMBL2105737
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Sonidegib
ATC Codes
L01XX48 — Sonidegib
AHFS Codes
Not Available
PDB Entries
Not Available
FDA label
Download (428 KB)
MSDS
Download (59.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0WithdrawnTreatmentResectable Pancreatic Cancers1
1Active Not RecruitingTreatmentAdvanced Breast Cancer1
1Active Not RecruitingTreatmentChronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndrome / Essential Thrombocythemia (ET) / Myelodysplastic Syndrome / Myelodysplastic/Myeloproliferative Neoplasms / Polycythemia Vera (PV) / Previously Treated Myelodysplastic Syndromes / Primary Myelofibrosis / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
1Active Not RecruitingTreatmentHepatocellular,Carcinoma / Liver Cirrhosis1
1Active Not RecruitingTreatmentMalignant Neoplasm of Pancreas1
1Active Not RecruitingTreatmentRecurrent Ovarian Cancer1
1CompletedNot AvailableAdvanced Pancreatic Adenocarcinoma / Advanced Solid Tumors / Dose Escalation / Gastroesophageal Junction Cancer / Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer / Malignant Neoplasm of Stomach / Metastatic Breast Cancer (MBC) / Metastatic Colorectal Cancers / Preliminary Efficacy / Recurrent Glioblastoma Multiforme / Safety / Triple Negative Metastatic Breast Cancer1
1CompletedTreatmentAdvanced Solid Tumors1
1CompletedTreatmentBasal Cell Carcinoma (BCC) / Cancer, Advanced Solid Tumors / Medulloblastomas2
1CompletedTreatmentCancer, Ovarian / Tumors, Solid1
1CompletedTreatmentImpaired Hepatic Function / Normal Hepatic Function1
1CompletedTreatmentLung Cancers1
1CompletedTreatmentMalignant Neoplasm of Pancreas1
1CompletedTreatmentPhiladelphia Chromosome Positive Chronic Myelogenous Leukemia1
1CompletedTreatmentProstate Cancer1
1RecruitingTreatmentEsophageal Cancers1
1TerminatedTreatmentGraft Versus Host Disease (GVHD)1
1Unknown StatusTreatmentProstate Cancer1
1, 2Active Not RecruitingTreatmentBlood Platelet Disorders / Bone Marrow Diseases / Disorders, Blood Coagulation / Essential Thrombocythemia (ET) / Hematologic Diseases / Hemorrhagic Disorders / Myeloproliferative Disorders / Primary Myelofibrosis / Thrombocytosis1
1, 2Active Not RecruitingTreatmentResectable Pancreatic Adenocarcinoma1
1, 2CompletedTreatmentAstrocytomas / Gliomas / Hepatoblastomas / Medulloblastomas / Neuroblastomas / Rhabdomyosarcomas1
2Active Not RecruitingTreatmentBasal Cell Carcinoma (BCC)1
2CompletedTreatmentBasal Cell Carcinoma (BCC) / Gorlin's Syndrome / Nevoid Basal Cell Carcinoma Syndrome1
2CompletedTreatmentLeukaemia, Acute1
2CompletedTreatmentMedulloblastomas1
2CompletedTreatmentTreatment for Basal Cell Carcinomas (BCCs) in Gorlin Syndrome Patients1
2RecruitingTreatmentRecurrent Plasma Cell Myeloma / Refractory Multiple Myeloma / Refractory Plasma Cell Myeloma1
2TerminatedTreatmentMultiple Myeloma (MM)1
2TerminatedTreatmentPTCH1 or SMO Activated Solid and Hematologic Tumors1
2TerminatedTreatmentSporadic Superficial and Nodular Skin Basal Cell Carcinomas1
2WithdrawnTreatmentNeoplasms, Breast1
2, 3WithdrawnTreatmentBasal Cell Carcinoma (BCC)1
Not AvailableActive Not RecruitingTreatmentBasal Cell Carcinoma of the Skin / Nevoid Basal Cell Carcinoma Syndrome / Recurrent Skin Cancer1
Not AvailableCompletedTreatmentBasal Cell Carcinoma (BCC)1
Not AvailableWithdrawnTreatmentPancreatic Ductal Adenocarcinoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
CapsuleOral200 mg
CapsuleOral200 mg/1
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8178563 No2009-02-062029-02-06Us
US8063043 No2009-09-152029-09-15Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00155 mg/mLALOGPS
logP5.64ALOGPS
logP6.76ChemAxon
logS-5.5ALOGPS
pKa (Strongest Acidic)14.21ChemAxon
pKa (Strongest Basic)5.45ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area63.69 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity125.34 m3·mol-1ChemAxon
Polarizability49.91 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted LC-MS/MS Spectrum - 10V, PositivePredicted LC-MS/MSNot Available
Predicted LC-MS/MS Spectrum - 20V, PositivePredicted LC-MS/MSNot Available
Predicted LC-MS/MS Spectrum - 40V, PositivePredicted LC-MS/MSNot Available
Predicted LC-MS/MS Spectrum - 10V, NegativePredicted LC-MS/MSNot Available
Predicted LC-MS/MS Spectrum - 20V, NegativePredicted LC-MS/MSNot Available
Predicted LC-MS/MS Spectrum - 40V, NegativePredicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as biphenyls and derivatives. These are organic compounds containing to benzene rings linked together by a C-C bond.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Biphenyls and derivatives
Direct Parent
Biphenyls and derivatives
Alternative Parents
o-Toluamides / Benzamides / Phenoxy compounds / Phenol ethers / Benzoyl derivatives / Dialkylarylamines / Aminopyridines and derivatives / Imidolactams / Morpholines / Heteroaromatic compounds
show 9 more
Substituents
Biphenyl / Benzamide / Benzoic acid or derivatives / O-toluamide / Toluamide / Phenoxy compound / Benzoyl / Phenol ether / Dialkylarylamine / Aminopyridine
show 28 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Wnt-protein binding
Specific Function
G protein-coupled receptor that probably associates with the patched protein (PTCH) to transduce the hedgehog's proteins signal. Binding of sonic hedgehog (SHH) to its receptor patched is thought t...
Gene Name
SMO
Uniprot ID
Q99835
Uniprot Name
Smoothened homolog
Molecular Weight
86395.95 Da
References
  1. Burness CB: Sonidegib: First Global Approval. Drugs. 2015 Sep;75(13):1559-66. doi: 10.1007/s40265-015-0458-y. [PubMed:26323341 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Burness CB: Sonidegib: First Global Approval. Drugs. 2015 Sep;75(13):1559-66. doi: 10.1007/s40265-015-0458-y. [PubMed:26323341 ]
Drug created on October 01, 2015 09:13 / Updated on September 01, 2017 12:02